Dr. Jennifer Lovejoy is a senior executive and biobehavioral scientist with deep experience in personalized medicine. During her academic career, Dr. Lovejoy held the Manship Endowed Professorship in Diabetes at LSU's Pennington Biomedical Research Center. She is a Past-President of the Obesity Society and has published over 80 peer-reviewed papers on her research. More recently, Dr. Lovejoy was Chief Translational Science Officer at Arivale, a precision medicine startup uniting systems biology and behavioral science to help consumers optimize wellness. Currently, she is the SVP, Head of Research at Calibrate, a company that combines FDA-approved weight loss medications with personalized lifestyle interventions to help individuals improve metabolic health.
I am a tenure-track Assistant Professor in the Department of Epidemiology at Johns Hopkins Bloomberg School of Public Health, a Core Faculty member in the Welch Center for Prevention, Epidemiology and Clinical Research. My research examines the nutritional, microbial, and environmental determinants of health across the lifespan, with the ultimate goal of identifying modifiable targets for chronic disease prevention and treatment. I believe that primary prevention of disease risk factors, in early life and among high-risk populations, provides the greatest opportunity to curb contemporary chronic disease epidemics and reduce health disparities. Accordingly, many of my investigations, in both local and global contexts, are in young, racially and ethnically diverse populations. A large part of my research focuses on the role of the human microbiome in nutrition and disease. I am particularly intrigued by the microbiome because it is amenable to intervention.
Sharpening Nutrition Science with the Microbiome
In this talk I will provide an overview of how the intestinal microbiota and their metabolites can inform more precise approaches to prevention and treatment of nutrition-related cardiometabolic diseases, including obesity, type 2 diabetes and obesity in both children and adults.
Dr. Hood is currently on the faculty of the Institute for Systems Biology and CEO of Phenome Health, a non-profit organization driving the emergence of precision population health. He received an MD from Johns Hopkins Medical School and a PhD from Caltech. A professor at Caltech for 22 years, a co-founder and chairman of the first cross-disciplinary biology department at the University of Washington for 8 years; a co-founder and president of the Institute for Systems Biology for 18 years—the first organization promoting systems biology. He has co-founded 17 biotech companies; has 18 honorary degrees from leading institutions all over the world. He is in three US National Academies: Science, Medicine and Engineering. He developed the automated DNA sequencer that made the human genome sequence possible. He is pioneering data-driven and systems-driven 21st century medicine to transform healthcare.
Precision Population Health: A Million Person Project
Beyond the Human Genome (BHG), a second Human Genome Project, will analyze the genomes/phenomes for one million people over 10 years. BGH’s mission is to employ this data-driven approach to make a life of health accessible to all people. We are looking for partners from across the healthcare spectrum.
Dr. Mahoney has expertise in precision health, practice transformation, and care model redesign in large academic health care systems. She has served in senior level positions at AMCs in the U.S. and internationally, developing innovative and transformative approaches to proactive and personalized team-based primary care that empowers patients, health care providers, and communities. As Chief of the Medical Staff, she provides oversight of quality, safety, and professionalism activities of the 3000 physicians within Stanford Health Care. Dr. Mahoney earned her B.A in Molecular and Cellular Biology at the University of California Berkeley, her M.D. at the University of California San Francisco, and her M.B.A. at Brandeis University.